Comparative in vitro activity of norfloxacin and seven other antimicrobial agents against clinical isolates from urinary tract infections.
The in vitro activity of norfloxacin, a new quinolone derivative, was tested against 469 clinical isolates derived mainly from urinary samples from outpatients. It inhibited all Escherichia coli, Klebsiella oxytoca and Proteus strains at a concentration of 0.25 micrograms/ml, and all Pseudomonas aeruginosa, Enterobacter, Klebsiella pneumoniae, Staphylococcus and Enterococcus strains at a concentration of 8 micrograms/ml or less. Norfloxacin proved to be more effective than nalidixic acid, trimethoprim, mecillinam and nitrofurantoin against all gram-negative rods tested.
Esko
E
E
Renkonen
O V
OV
D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology*; D002433:Cefaclor / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D004756:Enterobacteriaceae Infections / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D009643:Norfloxacin; D010406:Penicillins / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects*; D013290:Streptococcal Infections / Q000382:microbiology; D013291:Streptococcus / Q000187:drug effects*; D014552:Urinary Tract Infections / Q000382:microbiology*
D000892:Anti-Infective Agents, Urinary; D010406:Penicillins; D009268:Nalidixic Acid; D002433:Cefaclor; D009643:Norfloxacin